Histone-deacetylase inhibitors: novel drugs for the treatment of cancer
The DOI matches its Crossref record; 120 of the 121 references it cites were found in a registry or an index.
Abstract
The opposing actions of histone acetyltransferases (HATs) and histone deacetylases (HDACs) allow gene expression to be exquisitely regulated through chromatin remodelling. Aberrant transcription due to altered expression or mutation of genes that encode HATs, HDACs or their binding partners, is a key event in the onset and progression of cancer. HDAC inhibitors can reactivate gene expression and inhibit the growth and survival of tumour cells. The remarkable tumour specificity of these compounds, and their potency in vitro and in vivo, underscore the potential of HDAC inhibitors as exciting new agents for the treatment of cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Acetylation of the core histones of nucleosomes strongly influences gene transcription (Khochbin et al., 2001; Johnstone, 2002).”
From Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases (2004) · cites this paper as Johnstone, 2002
In the citing paper
“Class I HDACs are ubiquitously expressed and are primarily located in the nucleus, while the class II enzymes can shuttle between the nucleus and cytoplasm and demonstrate tissue-specific expression (Johnstone, 2002; Marks et al., 2001; Vigushin and Coombes, 2002).”
From Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases (2004) · cites this paper as Johnstone, 2002
In the citing paper
“Two related classes of eukaryotic zinc-containing HDACs have been recognized based upon sequence similarity: class I (HDAC1, 2, 3, and 8) and class II (HDAC4, 5, 6, 7, 9, and 10) (Johnstone, 2002; Gao et al., 2002).”
From Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases (2004) · cites this paper as Johnstone, 2002
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Jenuwein, T., & Allis, C. D. (2001) · Science · doi:10.1126/science.1063127 · Cited by 9,756 · cited 1×
“In general terms, condensed chromatin mediates transcriptional repression, whereas transcriptionally active genes are in areas of open chromati”
BackgroundCrystal structure of the nucleosome core particle at 2.8 Å resolution
Luger, K., Mäder, A. W., Richmond, R. K., Sargent, D. F., & Richmond, T. J. (1997) · Nature · doi:10.1038/38444 · Cited by 9,466
Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase
Imai, S.-I., Armstrong, C. M., Kaeberlein, M., & Guarente, L. (2000) · Nature · doi:10.1038/35001622 · Cited by 3,510 · cited 1×
“pl?locus=sir2">Sir2 , a yeast transcriptional repressor that requires the cofactor NAD + for its deacetylase activit”
BackgroundhSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase
Vaziri, H., Dessain, S. K., Eaton, E. N., Imai, S.-I., Frye, R. A., Pandita, T. K., Guarente, L., & Weinberg, R. A. (2001) · Cell · doi:10.1016/s0092-8674(01)00527-x · Cited by 2,659 · cited 3×
“Histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of DAXX in acute promyelocytic leukaemia with t(15;17).”
Negative Control of p53 by Sir2α Promotes Cell Survival under Stress
Luo, J., Nikolaev, A. Y., Imai, S.-I., Chen, D., Su, F., Shiloh, A., Guarente, L., & Gu, W. (2001) · Cell · doi:10.1016/s0092-8674(01)00524-4 · Cited by 2,081
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
Gottlicher, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.6969 · Cited by 1,887 · cited 1×
“asp?DrugCode=1%2D1882&DrugName=VALPROIC+ACID+ORAL&DrugType=1">valproic acid , inhibit HDAC activity and affect the expression of numerous genes with disparate cellular function”
BackgroundHistone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866 · cited 1×
“gov/cancer_information/cancer_type/leukemia/">leukaemias and solid tumours to express differentiated characteristics and stop proliferatin”
BackgroundCameron, E. E., Bachman, K. E., Myöhänen, S., Herman, J. G., & Baylin, S. B. (1999) · Nature Genetics · doi:10.1038/5047 · Cited by 1,857
Acetylation of Histones and Transcription-Related Factors
Sterner, D. E., & Berger, S. L. (2000) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.64.2.435-459.2000 · Cited by 1,780 · cited 5×
“Mechanisms of transcriptional repression by the t(8;21)-, t(12;21)-, and inv(16)-encoded fusion proteins.”
BackgroundInfluential
Research works printed but not linked: 1
- Ruefli, A. A. Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-gp expressing cells. Int. J. Cancer. (in the press).
Cited by
Items 101–200 of 1,001
Modification of Proteins by Metabolites in Immunity
Diskin, C., Ryan, T. A. J., & O’Neill, L. A. J. (2021) · Immunity · doi:10.1016/j.immuni.2020.09.014 · Cited by 209
Bradner, J. E., Mak, R., Tanguturi, S. K., Mazitschek, R., Haggarty, S. J., Ross, K., Chang, C. Y., Bosco, J., West, N., Morse, E., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006774107 · Cited by 211
“However, all clinically-used HDAC inhibitors are perceived to be relatively nonspecific, acting to inhibit multiple class I and II deacetylases (28).”
BackgroundMolecularly Targeted Oncology Therapeutics and Prolongation of the QT Interval
Strevel, E. L., Ing, D. J., & Siu, L. L. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6925 · Cited by 211
Camphausen, K., Burgan, W., Cerra, M., Oswald, K. A., Trepel, J. B., Lee, M.-J., & Tofilon, P. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2630 · Cited by 209
“Whereas oncogenesis has been associated with histone acetyltransferase inactivation, it is aberrant HDAC activity leading to the transcriptional repression of tumor suppressor genes that is considered a common event contributing to tumor formation (3).”
BackgroundThe Activity of Antiepileptic Drugs as Histone Deacetylase Inhibitors
Eyal, S., Yagen, B., Sobol, E., Altschuler, Y., Shmuel, M., & Bialer, M. (2004) · Epilepsia · doi:10.1111/j.0013-9580.2004.00104.x · Cited by 205
“Epilepsia, 45(7):737–744, 2004 Blackwell Publishing, Inc.”
Shen, L., Ciesielski, M., Ramakrishnan, S., Miles, K. M., Ellis, L., Sotomayor, P., Shrikant, P., Fenstermaker, R., & Pili, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030815 · Cited by 202
“HDACs have been shown to be involved in oncogenic transformation by mediating the transcriptional regulation of genes that are involved in cell cycle progression, proliferation, and apoptosis [16,17].”
BackgroundJones, R. B., O'Connor, R., Mueller, S., Foley, M., Szeto, G. L., Karel, D., Lichterfeld, M., Kovacs, C., Ostrowski, M. A., Trocha, A., et al. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004287 · Cited by 206
“Second, in addition to altering histone acetylation status, and thus chromatin structure, HDACis can interact with multiple transcription factors, including NF-kB, AP-1, and others either by interfering with co-repressor HDAC enzymes that are recruited to transcription factor binding sites resulting in enhanced transc…”
BackgroundTeratogenic mechanisms of medical drugs
van Gelder, M. M. H. J., van Rooij, I. A. L. M., Miller, R. K., Zielhuis, G. A., de Jong-van den Berg, L. T. W., & Roeleveld, N. (2010) · Human Reproduction Update · doi:10.1093/humupd/dmp052 · Cited by 204
“HDACs deacety-late lysine residues on histone tails and condensate chromatin, resulting in limited access of transcriptional activators to the DNA (Johnstone, 2002).”
InfluentialWhole cereal grains and potential health effects: Involvement of the gut microbiota
Gong, L., Cao, W., Chi, H., Wang, J., Zhang, H., Liu, J., & Sun, B. (2018) · Food Research International · doi:10.1016/j.foodres.2017.10.025 · Cited by 206
Direct Conversion of C. elegans Germ Cells into Specific Neuron Types
Tursun, B., Patel, T., Kratsios, P., & Hobert, O. (2011) · Science · doi:10.1126/science.1199082 · Cited by 206
Haggarty, S. J., Koeller, K. M., Wong, J. C., Butcher, R. A., & Schreiber, S. L. (2003) · Chemistry & Biology · doi:10.1016/s1074-5521(03)00095-4 · Cited by 201
Fouladi, M., Park, J. R., Stewart, C. F., Gilbertson, R. J., Schaiquevich, P., Sun, J., Reid, J. M., Ames, M. M., Speights, R., Ingle, A. M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9119 · Cited by 199
Prostate specific antigen gene regulation by androgen receptor
Kim, J., & Coetzee, G. A. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20228 · Cited by 198
HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses
Bolden, J. E., Shi, W., Jankowski, K., Kan, C.-Y., Cluse, L., Martin, B. P., MacKenzie, K. L., Smyth, G. K., & Johnstone, R. W. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.9 · Cited by 192
Self-citationSundar, I. K., Yao, H., & Rahman, I. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4863 · Cited by 193
“Based on the existence of tandem deacetylase domains, class II HDACs are further classified into class IIa (HDACs, 4, 5, 7, and 9) and class IIb (HDACs 6 and 10) (62).”
BackgroundQuantitative Proteomic Analysis of Post-translational Modifications of Human Histones
Beck, H. C., Nielsen, E. C., Matthiesen, R., Jensen, L. H., Sehested, M., Finn, P., Grauslund, M., Hansen, A. M., & Jensen, O. N. (2006) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m600007-mcp200 · Cited by 194
“Inhibition of HDAC activity results in hyperacetylation of lysine residues in the NH2 tails of histones H3 and H4 (10), and it leads to the expression of genes that induce growth arrest, cell differentiation, and apoptotic cell death in cultured tumor cells (11, 12).”
BackgroundBajaj, S., Asati, V., Singh, J., & Roy, P. P. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.04.051 · Cited by 187
Young, D. A., Lakey, R. L., Pennington, C. J., Jones, D., Kevorkian, L., Edwards, D. R., Cawston, T. E., & Clark, I. M. (2005) · Arthritis Research & Therapy · doi:10.1186/ar1702 · Cited by 193
“Discussion HDAC inhibitors are currently being developed as cancer therapeutics, largely by virtue of their impact upon the cell cycle and apoptosis [30] in transformed cells.”
BackgroundDevelopment of the first small molecule histone deacetylase 6 (HDAC6) degraders
Yang, K., Song, Y., Xie, H., Wu, H., Wu, Y.-T., Leisten, E. D., & Tang, W. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.05.057 · Cited by 190
Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid
Camphausen, K., Cerna, D., Scott, T., Sproull, M., Burgan, W. E., Cerra, M. A., Fine, H., & Tofilon, P. J. (2005) · International Journal of Cancer · doi:10.1002/ijc.20774 · Cited by 190
Requirement of Histone Deacetylase Activity for Signaling by STAT1
Klampfer, L., Huang, J., Swaby, L.-A., & Augenlicht, L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401359200 · Cited by 189
Wang, L., de Zoeten, E. F., Greene, M. I., & Hancock, W. W. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd3031 · Cited by 186
Mai, A., Massa, S., Pezzi, R., Simeoni, S., Rotili, D., Nebbioso, A., Scognamiglio, A., Altucci, L., Loidl, P., & Brosch, G. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049002a · Cited by 184
Down-regulation of Histone Deacetylases Stimulates Adipocyte Differentiation
Yoo, E. J., Chung, J.-J., Choe, S. S., Kim, K. H., & Kim, J. B. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m508982200 · Cited by 182
WNT7a induces E-cadherin in lung cancer cells
Ohira, T., Gemmill, R. M., Ferguson, K., Kusy, S., Roche, J., Brambilla, E., Zeng, C., Baron, A., Bemis, L., Erickson, P., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1734137100 · Cited by 182
Kumagai, T., Wakimoto, N., Yin, D., Gery, S., Kawamata, N., Takai, N., Komatsu, N., Chumakov, A., Imai, Y., & Koeffler, H. P. (2007) · International Journal of Cancer · doi:10.1002/ijc.22558 · Cited by 182
“Inappropriate transcriptional repression of tumor suppressor genes mediated by HDACs may be a common molecular mechanism associated with tumorigenesis.(8) In addition, HAT and HDACs can directly modify proteins, including transcriptional factors; these changes can either enhance or dampen the activity of the protein.”
BackgroundDevelopment of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity
Wu, H., Yang, K., Zhang, Z., Leisten, E. D., Li, Z., Xie, H., Liu, J., Smith, K. A., Novakova, Z., Barinka, C., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00516 · Cited by 180
HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma
Singh, T. R., Shankar, S., & Srivastava, R. K. (2005) · Oncogene · doi:10.1038/sj.onc.1208585 · Cited by 177
Histone Deacetylase Inhibitors In The Treatment Of Cancer: Overview And Perspectives
Giannini, G., Cabri, W., Fattorusso, C., & Rodriquez, M. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.80 · Cited by 175
The Gut Microbial Bile Acid Modulation and Its Relevance to Digestive Health and Diseases
Fogelson, K. A., Dorrestein, P. C., Zarrinpar, A., & Knight, R. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.02.022 · Cited by 177
TNF-related apoptosis-inducing ligand (TRAIL): A new path to anti-cancer therapies
Holoch, P. A., & Griffith, T. S. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.06.066 · Cited by 178
“Histone deacetylase inhibitors are a new class of antitumor drugs that influence gene expression by promoting acetylation of histones (Johnstone, 2002), and have been found to upregulate TRAIL receptor-2 and sensitize various tumor cells to TRAIL-induced apoptosis (Fulda and Debatin, 2005b; Nakata…”
BackgroundAdvances in targeting histone deacetylase for treatment of solid tumors
Shi, M.-Q., Xu, Y., Fu, X., Pan, D.-S., Lu, X.-P., Xiao, Y., & Jiang, Y.-Z. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01551-8 · Cited by 161
“To this end, several different HDACis have already been evaluated in clinical trials, highlighting the ongoing efforts to refine treatment strategies and enhance patient outcomes [88, 89].”
BackgroundA novel histone deacetylase pathway regulates mitosis by modulating Aurora B kinase activity
Li, Y., Kao, G. D., Garcia, B. A., Shabanowitz, J., Hunt, D. F., Qin, J., Phelan, C., & Lazar, M. A. (2006) · Genes & Development · doi:10.1101/gad.1455006 · Cited by 176
Proteinases involved in matrix turnover during cartilage and bone breakdown
Cawston, T. E., & Young, D. A. (2010) · Cell and Tissue Research · doi:10.1007/s00441-009-0887-6 · Cited by 173
Porcu, M., & Chiarugi, A. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.12.009 · Cited by 173
Is there a future for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders
Grayson, D. R., Kundakovic, M., & Sharma, R. P. (2010) · Molecular Pharmacology · doi:10.1124/mol.109.061333 · Cited by 171
“As indicated previously, the majority of the currently available HDAC inhibitors block all classic HDACs, and the recent focus in HDAC inhibitor development has been on improvement in specificity to overcome the nonspecific cytotoxicity of these drugs (Johnstone, 2002; Balasubramanian et al., 2009).”
BackgroundEpigenetic mechanisms in the context of complex diseases
van Vliet, J., Oates, N. A., & Whitelaw, E. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-6526-z · Cited by 173
Ku70 acetylation mediates neuroblastoma cell death induced by histone deacetylase inhibitors
Subramanian, C., Opipari, A. W., Bian, X., Castle, V. P., & Kwok, R. P. S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408351102 · Cited by 172
IFN Unresponsiveness in LNCaP Cells Due to the Lack of JAK1 Gene Expression
Dunn, G. P., Sheehan, K. C. F., Old, L. J., & Schreiber, R. D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4316 · Cited by 173
“Many studies have shown that classic tumor suppressors, including BRCA1, APC, Rb, VHL, and TP53, are often repressed in cancers through methylation or through mechanisms involving histone deacetylation (36, 37).”
BackgroundBackliwal, G., Hildinger, M., Kuettel, I., Delegrange, F., Hacker, D. L., & Wurm, F. M. (2008) · Biotechnology and Bioengineering · doi:10.1002/bit.21882 · Cited by 170
Serpe, L., Catalano, M. G., Cavalli, R., Ugazio, E., Bosco, O., Canaparo, R., Muntoni, E., Frairia, R., Gasco, M. R., Eandi, M., et al. (2004) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2004.03.026 · Cited by 165
“The combination of HDIs and conventional antineoplastic drugs has been suggested as a potential new approach in cancer treatment [27].”
BackgroundEpigenetics in non-small cell lung cancer: from basics to therapeutics
Ansari, J., Shackelford, R. E., & El-Osta, H. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.02.02 · Cited by 164
“A large number of studies have demonstrated that alteration in cytosine hypermethylation has diagnostic and prognostic value in lung cancer (82,102,105-122), and in some cases appears to predict treatment responses (137139,141-143,145-147).”
BackgroundInfluentialMeehan, W. J., Samant, R. S., Hopper, J. E., Carrozza, M. J., Shevde, L. A., Workman, J. L., Eckert, K. A., Verderame, M. F., & Welch, D. R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m307969200 · Cited by 170
Bettini, M. L., Pan, F., Bettini, M., Finkelstein, D., Rehg, J. E., Floess, S., Bell, B. D., Ziegler, S. F., Huehn, J., Pardoll, D. M., et al. (2012) · Immunity · doi:10.1016/j.immuni.2012.03.020 · Cited by 166
“However, HDAC7 has also been suggested to deacetylate the ε-acetyllysine residues found on Foxp3, suggesting a level of complexity that has yet to be fully understood (Johnstone, 2002; Saouaf et al., 2009).”
Neugebauer, R. C., Uchiechowska, U., Meier, R., Hruby, H., Valkov, V., Verdin, E., Sippl, W., & Jung, M. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm700972e · Cited by 166
Bowers, A., West, N., Taunton, J., Schreiber, S. L., Bradner, J. E., & Williams, R. M. (2008) · Journal of the American Chemical Society · doi:10.1021/ja8033763 · Cited by 165
Recent Advances in the Development of Polyamine Analogues as Antitumor Agents
Casero, R. A., & Woster, P. M. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900187v · Cited by 166
Duiker, E. W., Mom, C. H., de Jong, S., Willemse, P. H. B., Gietema, J. A., van der Zee, A. G. J., & de Vries, E. G. E. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.03.018 · Cited by 166
“Phase I and II studies with several HDAC inhibitors are ongoing.(57) Other novel drugs that enhance apoptosis when combined”
BackgroundHaller, D., Russo, M. P., Sartor, R. B., & Jobin, C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205737200 · Cited by 165
Rössig, L., Urbich, C., Brühl, T., Dernbach, E., Heeschen, C., Chavakis, E., Sasaki, K.-I., Aicher, D., Diehl, F., Seeger, F., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20042097 · Cited by 163
“Of note, the inhibition of adult vasculogenesis by HDAC inhibitors may also contribute to the reported profound antitumor activity of HDAC inhibitors (15).”
BackgroundPlaying the DISC: Turning on TRAIL death receptor-mediated apoptosis in cancer
Pennarun, B., Meijer, A., de Vries, E. G. E., Kleibeuker, J. H., Kruyt, F., & de Jong, S. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.11.004 · Cited by 162
Geng, L., Cuneo, K. C., Fu, A., Tu, T., Atadja, P. W., & Hallahan, D. E. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0049 · Cited by 163
“gene expression in cancer cell lines (11, 12).”
BackgroundInhibition of Histone Deacetylation: A Strategy for Tumor Radiosensitization
Camphausen, K., & Tofilon, P. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6202 · Cited by 162
HDACi – Targets beyond chromatin
Buchwald, M., Krämer, O. H., & Heinzel, T. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.02.028 · Cited by 159
“Re-expression of down-regulated genes essential for growth inhibition and cell death, as well as the alteration of abnormal acetylation pattern of non-histone proteins, are considered as a viable approach in cancer therapy [9,19].”
BackgroundThe epigenetics of ovarian cancer drug resistance and resensitization
Balch, C., Huang, T. H.-M., Brown, R., & Nephew, K. P. (2004) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.05.025 · Cited by 160
Shankar, S., & Srivastava, R. K. (2008) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4020-6554-5_13 · Cited by 160
Chabane, N., Zayed, N., Afif, H., Endam, L. M., Benderdour, M., Boileau, C., Martel‐Pelletier, J., Pelletier, J., Duval, N., & Fahmi, H. (2008) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2008.03.009 · Cited by 158
Histone deacetylases: target enzymes for cancer therapy
Mottet, D., & Castronovo, V. (2007) · Clinical & Experimental Metastasis · doi:10.1007/s10585-007-9131-5 · Cited by 158
“However, several studies showed that HDACi activate pro-apoptotic proteins such as Bax [34–36], Bad [35, 37], Bim [35, 36], BAK [35, 36], Apaf-1 [38] and repress anti-apoptotic proteins such as Bcl-2 [33–35, 37, 39], Bcl-XL [35–37, 39, 40], XIAP [35, 39], Mcl-1 [35, 36, 39] and survivin [17, 18, 41], thereby increasin…”
BackgroundCrystal Structure of a Bacterial Class 2 Histone Deacetylase Homologue
Nielsen, T. K., Hildmann, C., Dickmanns, A., Schwienhorst, A., & Ficner, R. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.09.065 · Cited by 173
Negative regulation of histone deacetylase 8 activity by cyclic AMP-dependent protein kinase A
Lee, H., Rezai-Zadeh, N., & Seto, E. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.2.765-773.2004 · Cited by 153
“agents for the treatment of certain forms of cancer (22, 23, 27).”
BackgroundTrapp, J., Jochum, A., Meier, R., Saunders, L. R., Marshall, B. L., Kunick, C., Verdin, E. M., Goekjian, P. G., Sippl, W., & Jung, M. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060118b · Cited by 173
Hess‐Stumpp, H., Bracker, T. U., Henderson, D. A., & Politz, O. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.02.009 · Cited by 167
Inoue, S., MacFarlane, M., Harper, N., Wheat, L. M. C., Dyer, M. J. S., & Cohen, G. M. (2004) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401535 · Cited by 174
“in vivo and in vitro at nontoxic doses, have entered clinical trials.(24,25) The acetylation status of histones alters chromatin structure, thereby modulating gene expression, and is governed by the relative activities of histone acetyltransferases Cell Death and Differentiation (2004) 11, S193–S206 & 2004 Nature Publ…”
BackgroundHypoxic silencing of tumor suppressor RUNX3 by histone modification in gastric cancer cells
Lee, S. H., Kim, J., Kim, W.-H., & Lee, Y. M. (2008) · Oncogene · doi:10.1038/onc.2008.377 · Cited by 156
Development of histone deacetylase inhibitors for cancer treatment
Marchion, D., & Münster, P. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.4.583 · Cited by 149
“9 Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer.”
BackgroundInfluentialPaino, F., Noce, M. L., Tirino, V., Naddeo, P., Desiderio, V., Pirozzi, G., ROSA, A. D., Laino, L., Altucci, L., & Papaccio, G. (2013) · Stem Cells · doi:10.1002/stem.1544 · Cited by 156
“In addition, they induce cell cycle arrest and differentiation and/or apoptosis of tumor cell lines in vitro and in vivo [19,20].”
BackgroundZhang, K., Yau, P. M., Chandrasekhar, B., New, R., Kondrat, R. W., Imai, B. S., & Bradbury, M. (2004) · PROTEOMICS · doi:10.1002/pmic.200300503 · Cited by 157
Target-Based Approach to Inhibitors of Histone Arginine Methyltransferases
Spannhoff, A., Heinke, R., Bauer, I., Trojer, P., Metzger, E., Gust, R., Schüle, R., Brosch, G., Sippl, W., & Jung, M. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061250e · Cited by 163
Histone deacetylase inhibitors in hematological malignancies and solid tumors
Chun, P. (2015) · Archives of Pharmacal Research · doi:10.1007/s12272-015-0571-1 · Cited by 160
Tumor cell‐specific cytotoxicity by targeting cell cycle checkpoints
Warrener, R., Beamish, H., Burgess, A., Waterhouse, N. J., Giles, N., Fairlie, D. P., & Gabrielli, B. G. (2003) · The FASEB Journal · doi:10.1096/fj.02-1003fje · Cited by 154
“HDACI treatment has been reported to down-regulate expression of antiapoptotic proteins such as Bcl-XL and up-regulate one of the proapoptotic Bcl-2 family members such as Bax (8).”
BackgroundHistone deacetylase inhibitors open new doors in cancer therapy
McLaughlin, F., & Thangue, N. B. L. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.05.034 · Cited by 161
Characterization of the two catalytic domains in histone deacetylase 6
Zou, H., Wu, Y., Navre, M., & Sang, B. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.12.144 · Cited by 160
ZHAO, T., CHENG, G., ZHANG, L., TSENG, Y., & PADBURY, J. (2007) · Cardiovascular Research · doi:10.1016/j.cardiores.2007.08.010 · Cited by 141
“Notably, HDAC inhibition also resulted in remarkable acetylation of p38 at lysine residues.”
BackgroundPark, J., Jung, Y., Kim, T. Y., Kim, S. G., Jong, H.-S., Lee, S. E., Kim, D.-K., Lee, J., Kim, N. K., Kim, T., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0709 · Cited by 143
“These compounds are viewed as the first generation of HDAC inhibitors and fall into four classes, short-chain fatty acids, hydroxamic acids, cyclic tetrapeptides, and benzamides (3, 4).”
BackgroundInfluentialDietary fiber metabolites regulate innate lymphoid cell responses
Sepahi, A., Liu, Q., Friesen, L., & Kim, C. H. (2021) · Mucosal Immunology · doi:10.1038/s41385-020-0312-8 · Cited by 138
Dual targeting of epigenetic therapy in cancer
Hellebrekers, D. M. E. I., Griffioen, A. W., & van Engeland, M. (2006) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.07.003 · Cited by 162
The multifaceted influence of histone deacetylases on DNA damage signalling and DNA repair
Roos, W. P., & Krumm, A. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw922 · Cited by 139
Robert, C., & Rassool, F. V. (2012) · Advances in cancer research · doi:10.1016/b978-0-12-394387-3.00003-3 · Cited by 153
“now well documented that apoptosis induction is linked to its antitumor effects, as all the HDACis have been reported to induce apoptotic mechanisms (Carew, Giles, & Nawrocki, 2008; Johnstone, 2002; Marks, Richon, & Rifkind, 2000).”
BackgroundTseng (2010) · Oncology Reports · doi:10.3892/or.2010.1097 · Cited by 139
(Bis)urea and (Bis)thiourea Inhibitors of Lysine-Specific Demethylase 1 as Epigenetic Modulators
Sharma, S. K., Wu, Y., Steinbergs, N., Crowley, M. L., Hanson, A. S., Casero, R. A., & Woster, P. M. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100217a · Cited by 141
Paper-based cell culture platform and its emerging biomedical applications
Ng, K., Gao, B., Yong, K. W., Li, Y., Shi, M., Zhao, X., Li, Z., Zhang, X. H., Pingguan‐Murphy, B., Yang, H., et al. (2016) · Materials Today · doi:10.1016/j.mattod.2016.07.001 · Cited by 138
Deacetylase Activity Is Required for cAMP Activation of a Subset of CREB Target Genes
Fass, D. M., Butler, J. E. F., & Goodman, R. H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305905200 · Cited by 137
Iguchi, H., Urashima, Y., Inagaki, Y., Ikeda, Y., Okamura, M., Tanaka, T., Uchida, A., Yamamoto, T. T., Kodama, T., & Sakai, J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700460200 · Cited by 135
Lucas, D. M., Davis, M. E., Parthun, M. R., Mone, A. P., Kitada, S., Cunningham, K. D., Flax, E. L., Wickham, J., Reed, J. C., Byrd, J. C., et al. (2004) · Leukemia · doi:10.1038/sj.leu.2403388 · Cited by 143
Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs
Akimova, T., Ge, G., Golovina, T., Mikheeva, T., Wang, L., Riley, J. L., & Hancock, W. W. (2010) · Clinical Immunology · doi:10.1016/j.clim.2010.04.018 · Cited by 131
“Many HDACi are under investigation as anticancer agents since they are potent inducers of cancer cell growth arrest, differentiation and/or apoptotic cell death [18].”
BackgroundThe Design of Inhibitors for Medicinally Relevant Metalloproteins
Jacobsen, F. E., Lewis, J. A., & Cohen, S. M. (2007) · ChemMedChem · doi:10.1002/cmdc.200600204 · Cited by 132
Lyssiotis, C. A., Walker, J., Wu, C., Kondo, T., Schultz, P. G., & Wu, X. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707044104 · Cited by 132
Histone Deacetylase Inhibitors: Emerging Mechanisms of Resistance
Robey, R. W., Chakraborty, A. R., Basseville, A., Luchenko, V. L., Bahr, J. C., Zhan, Z., & Bates, S. E. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200329f · Cited by 145
Asnaghi, L., Calastretti, A., Bevilacqua, A., D’Agnano, I., Gatti, G., Canti, G. L., Delia, D., Capaccioli, S., & Nicolin, A. (2004) · Oncogene · doi:10.1038/sj.onc.1207698 · Cited by 138
Kirschbaum, M., Gojo, I., Goldberg, S. L., Bredeson, C., Kujawski, L. A., Yang, A., Marks, P., Frankel, P., Sun, X., Tosolini, A., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.13016 · Cited by 128
“HDAC inhibitors as single agents have been previously shown to affect a host of cellular targets and processes that might lead to antitumour activity in myeloid malignancies (eg, angiogenesis, apoptosis, the cell cycle, and tumour immunology) and have shown in vitro synergy with hypomethylating agents in various tumou…”
BackgroundYu, C., Rahmani, M., Almenara, J. A., Subler, M. A., Krystal, G. W., Conrad, D. H., Varticovski, L., Dent, P., & Grant, S. (2003) · PubMed · Cited by 143
Maggio, S. C., Rosato, R. R., Kramer, L. B., Dai, Y., Rahmani, M., Paik, D. S., Czarnik, A. C., Payne, S. G., Spiegel, S., & Grant, S. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2631 · Cited by 132
“Histone deacetylase (HDAC) inhibitors, including trichostatin A, sodium butyrate, suberoylanilide hydroxamic acid (SAHA), depsipeptide, MS-275, and aphicidin, among others, represent a novel and diverse class of agents that act by promoting histone acetylation (11).”
BackgroundInoue, S., Mai, A., Dyer, M. J. S., & Cohen, G. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4563 · Cited by 120
Jung, K. H., Noh, J. H., Kim, J. K., Eun, J. W., Bae, H. J., Xie, H. J., Chang, Y. G., Kim, M., Park, H., Lee, J. Y., et al. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24090 · Cited by 144
p53 Acetylation Is Crucial for Its Transcription-independent Proapoptotic Functions
Yamaguchi, H., Woods, N. T., Piluso, L. G., Lee, H.-H., Chen, J., Bhalla, K. N., Monteiro, A., Liu, X., Hung, M.-C., & Wang, H.-G. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m809268200 · Cited by 130
Choi, S. W., Braun, T., Chang, L., Ferrara, J. L. M., Pawarode, A., Magenau, J. M., Hou, G., Beumer, J. H., Levine, J. E., Goldstein, S., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70512-6 · Cited by 130
Remiszewski, S., Sambucetti, L. C., Bair, K. W., Bontempo, J., Cesarz, D., Chandramouli, N., Chen, R., Cheung, M., Cornell-Kennon, S., Dean, K., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030235w · Cited by 140
Hydroxyurea and hydroxamic acid derivatives as antitumor drugs
Šaban, N., & Bujak, M. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-0991-z · Cited by 143
Valproic Acid Attenuates Proteinuria and Kidney Injury
Van Beneden, K., Geers, C., Pauwels, M., Mannaerts, I., Verbeelen, D., van Grunsven, L. A., & Van den Branden, C. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010111196 · Cited by 129
Valproic Acid Induces Apoptosis and Cell Cycle Arrest in Poorly Differentiated Thyroid Cancer Cells
Catalano, M. G., Fortunati, N., Pugliese, M., Costantino, L., Poli, R., Bosco, O., & Boccuzzi, G. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1355 · Cited by 137
Metadata
- Authors
- Johnstone, R. W.
- Affiliations
- Peter MacCallum Cancer Centre (AU)
- Corresponding author
- Johnstone, Ricky W.
- ORCID
- Johnstone, Ricky W.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2002-04
- Volume
- 1
- Issue
- 4
- Pages
- 287-299
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1971621147
- Cited by
- 1,515
- References
- 121
- Citations by year
- 2026: 9 · 2025: 21 · 2024: 23 · 2023: 46 · 2022: 35 · 2021: 59 · 2020: 50 · 2019: 55 · 2018: 38 · 2017: 65 · 2016: 50 · 2015: 64 · 2014: 54 · 2013: 81 · 2012: 94
- FWCI
- 5.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- National Health and Medical Research Council
- National Medical Research Council
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- histone deacetylase inhibitors, histone acetyltransferase, chromatin remodeling, gene expression regulation, aberrant transcription, tumor cell growth inhibition, cancer therapy
- MeSH terms
- Acetylation, Animals, Antineoplastic Agents, Cell Differentiation, Chromatin, Clinical Trials as Topic, Enzyme Inhibitors, Histones, Humans, Neoplasms, Gene Expression Regulation, Neoplastic, Apoptosis, DNA Methylation, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.